Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$129.50 USD

129.50
949,567

+1.81 (1.42%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $129.00 -0.50 (-0.39%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (58 out of 244)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Zacks Equity Research

Neogen's (NEOG) Q2 Earnings Miss Estimates, 2024 View Down

by Zacks Equity Research

Neogen's (NEOG) Q2 revenues decline year over year due to lower Animal Safety business.

Zacks Equity Research

Veradigm (MDRX) & MedAllies Partner for Better Care Decisions

by Zacks Equity Research

Veradigm's (MDRX) partnership with MedAllies is likely to gain access to a wider range of patient data and drive better treatment decisions.

Zacks Equity Research

Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales

by Zacks Equity Research

Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.

Zacks Equity Research

Is Quest Diagnostics (DGX) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Cardinal Health (CAH) Streamlines Operation With New Structure

by Zacks Equity Research

Cardinal Health's (CAH) new reporting structure is likely to streamline operations, providing better visibility of growth areas. At-home solutions and OptiFreight Logistics are possibly the key value creators.

Nalak Das headshot

5 Mid-Cap Stocks to Buy in a Volatile January

by Nalak Das

We have narrowed our search to five mid-caps that have strong potential for 2024. These are: DVA, MNDY, GTLB, LNW, SRPT.

Zacks Equity Research

Here's Why Investors Should Retain Integra (IART) Stock Now

by Zacks Equity Research

Investors remain optimistic about Integra (IART) due to the positive outlook for its CSS segment.

Zacks Equity Research

Medtronic (MDT) Wins CE Mark for MiniMed 780G With Simplera Sync

by Zacks Equity Research

Medtronic (MDT) secures the CE Mark for the MiniMed 780G system with the disposable, all-in-one Simplera Sync CGM.

Benjamin Rains headshot

How to Find Great Momentum Stocks to Buy in 2024

by Benjamin Rains

The screen we explore today aims to find Zacks Rank #1 (Strong Buy) stocks that boast strong upward price momentum to help investors buy potential winners in January and throughout 2024.

Zacks Equity Research

Quest Diagnostics (DGX) to Boost Lab Services With New Buyout

by Zacks Equity Research

Quest Diagnostics' (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.

Zacks Equity Research

Here's Why You Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) owing to its strong Pharmacy model and geographical expansion.

Zacks Equity Research

QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind

by Zacks Equity Research

QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.

Zacks Equity Research

SenesTech's (SNES) New Partnership to Broaden Evolve's Scope

by Zacks Equity Research

The collaboration with a global leader in irrigation solutions for sustainable agriculture aligns with SenesTech's (SNES) target to introduce Evolve to a broader audience.

Zacks Equity Research

PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales

by Zacks Equity Research

PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.

Zacks Equity Research

Inspire Medical (INSP) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research

Inspire Medical's (INSP) revenue growth in the fourth quarter is likely to have been boosted by improved operating leverage.

Zacks Equity Research

DexCom (DXCM) Preliminary Q4 Revenues Ride on Sensor Demand

by Zacks Equity Research

DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.

Zacks Equity Research

Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio

by Zacks Equity Research

Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.

Zacks Equity Research

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

Investors are optimistic about National Vision's (EYE) stock, banking on strong solvency and promising future strategies.

Zacks Equity Research

Tandem Diabetes (TNDM) and Abbott Debut New Integrated Offering

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system to be integrated with Abbott's Freestyle Libre 2 Plus sensor.

Zacks Equity Research

Best Growth Stocks to Buy for January 9th

by Zacks Equity Research

EG, BROS and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 9, 2024.

Zacks Equity Research

Illumina (ILMN) Extends Partnership to Advance Cancer Test

by Zacks Equity Research

Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.

Zacks Equity Research

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) led by solid prospects in the Diagnostic business and raised guidance.

Zacks Equity Research

Chemed (CHE) Roto-Rooter Growth Continues, Macro Issues Hurt

by Zacks Equity Research

Within the Hospice segment, Chemed (CHE) is well poised to register growth driven by the growing aging population.

Zacks Equity Research

Asensus Surgical (ASXC) Completes Surgeon Lab for LUNA

by Zacks Equity Research

Asensus Surgical's (ASXC) latest Surgeon Lab helps it move closer to a finalized LUNA product.

Zacks Equity Research

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.